NCT02484001View on ClinicalTrials.gov

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

PHASE3CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

September 11, 2018

Study Completion Date

September 11, 2018

Conditions

Epilepsy

Interventions

DRUG

ESL 800 mg

one (1) tablet of 800 mg (QD).

DRUG

ESL 1200 mg

one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)

DRUG

ESL 1600 mg

two (2) tablets of 800 mg (QD).

DRUG

ESL 400 mg

half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT02484001 - Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures | Biotech Hunter | Biotech Hunter